Eating a plant-based evening meal reduced the risk of heart disease by 10 per cent when compared to those eating a fatty meat-filled dinner, the team from Harbin Medical University in China found.
People who eat too many refined carbs and fatty meats for dinner have a higher risk of heart disease than those who eat a similar diet for breakfast, according to a nationwide study published in the Endocrine Society s Journal of Clinical Endocrinology & Metabolism.
The mechanism by which the LNC00115/miR-7/ERK axis promotes cisplatin resistance provides a new strategy for combating cisplatin resistance in ovarian cancer
Peijia Medical s TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization
News provided by
Share this article
Share this article
SUZHOU, China, April 24, 2021 /PRNewswire/ A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne
® Transcatheter Aortic Valve Replacement System (hereinafter referred to as TaurusOne
® ) developed by Peijia Medical (Suzhou) Co., Ltd., located in Suzhou Industrial Park, Jiangsu Province, was officially approved for commercialization by the National Medical Products Administration of the PRC ( NMPA ) with registration number GXZZ 20213130275.
Academician Gao Runlin of Fuwai Hospital Chinese Academy of Medical Sciences served as Principal Investigator for the TaurusOne
26 aprile 2021 09:25
Fonte: Adnkronos
#salute-e-benessere
- SUZHOU, China, April 24, 2021 /PRNewswire/ A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne® Transcatheter Aortic Valve Replacement System (hereinafter referred to as TaurusOne® ) developed by Peijia Medical (Suzhou) Co., Ltd., located in Suzhou Industrial Park, Jiangsu Province, was officially approved for commercialization by the National Medical Products Administration of the PRC ( NMPA ) with registration number GXZZ 20213130275.
Academician Gao Runlin of Fuwai Hospital Chinese Academy of Medical Sciences served as Principal Investigator for the TaurusOne® registration clinical trial completed by National Centre for Cardiovascular Disease, Fuwai Hospital, The Second Affiliated Hospital ZheJiang University School of Medicine, West China Hospital of Sichuan University, General Hospital of Northern Theater Command, the Second Affilia